1Walldius G,Jungner I. The apoB/apoA-工 ratio: a strong,new risk factor for cardiovascular disease and a target forlipid-lowering therapy—a review of the evidence[J]. J InternMed’2006’259(5) :493-519.
2Vrablik M,Ceska R,Horinek A. Major apolipoprotein B*100mutations in lipoprotein metabolism and atherosclerosis [J].Physiol Res, 2001,50(4):337-343.
3Packard CJ. Understanding coronary heart disease as a consequenceof defective regulation of apolipoprotein B metabolism [ J].Curr Opin Lipidol, 1999,10(3) :237-244.
4Marcovina S,Packard CJ. Measurement and meaning ofapolipoprotein Al and apolipoprotein B plasma levels [J]. JIntern Med, 2006,259(5) :437-446.
5Grundy SM Low-density lipoprotein, non-high-density lipoprotein*and apolipoprotein B as targets of lipid-lowering therapy[J].Circulation, 2002 ’ 106(20) :2526-2529.
9Chambenoit 0,Hamon Y, Marguet D,et al. Specific dockingof apolipoprotein A- I at the cell surface requires a functionalABCAl transporter [ J ]. J Biol Chem, 2001, 276 ( 13 ):9955-9960.
10Feng Y,Lievens J, Jacobs F, et al, Hepatocyte-specificABCAl transfer increases HDL cholesterol but impairs HDLfunction and accelerates atherosclerosis[J]. Cardiovasc Res,2010,88C2):376-385.
31，Cooper GR,Henderson LO, Jay Smith S.Clinical Applications and standar dization of Apoliprotein measurements in the Diagnostic Workup of lipid Disorder s.Clin Chem,1991;37:619
42，Graziani MS,Zanolla L,Righetti G et al.Plasma apolipoprotein A1 and B in su rvivous of myocardial infarction and in a control group.Clin Chem，1998；44:134
64，Walmsley TA,Susan Grant,Peter MG,Effect of Plasma Triglyceride Concentrations on the Accuracy of immunoturbidimetric assay of apolipoprotein B.Clin Chem，19 91；37:748
75，Dupuy G,Jaillard H,Besson S et al.Automated immunoturbidimetric assay of Apol iproteins A1 and B Using Undiluted Samples.Clin Chem，1992；38:1065
86，Marcovina SM,Albers JJ,Kennedy H et al.International Federation of Clinical C hemistry Standardization Project For Measurements of Apolipopreteins A1 and B. Clin Chem，1994；40:586
97，Contois JH,Mcnamara JR,Lamul-Keefe CJ et al.Reference intervals for plasma a polipoprotein A1 determined with a standardized commercial immunoturbidimetric assay.Clin Chem，1996；42:507
10Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA, 2001,285:2486-2497.
4Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction[J]. Circulation, 2012, 126(16):2020-2035.
5Walldius G, Jungner I.The apoB/apoA- I ratio:a strong, new risk factor for cardiovascular disease and a target for fipid-lowering therapy-a review of the evidence[J]. J Intern Med, 2006, 259(5):493-519.
6BhaUa V, Georgiopoulou V, Gupta D, et al. Apolipoprotein A-1 Levels and Heart Failure Outcomes[J]. J CARD FAIL, 2012, 18(8):$71-$72.
